Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Rang in Aktien #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Aktienkurs
$9.60
Zuletzt synchronisiert: 2025-05-21
Marktkapitalisierung
$1.08B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel OptiNose, Inc. (OPTN)

Kategorie

P/B-Verhältnis für OptiNose, Inc. (OPTN)
P/B-Verhältnis zum August 2026 TTM: -2.42
Laut den neuesten Finanzberichten und dem Aktienkurs von OptiNose, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) -2.42. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei -25.04.
P/B-Verlauf für OptiNose, Inc. von 2015 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) -2.42 43.80%
2024 -1.68 -93.29%
2023 -25.04 792.27%
2022 -2.81 -95.58%
2021 -63.45 -114.37%
2020 441.64 369.60%
2019 94.05 201.63%
2018 31.18 -49.24%
2017 61.42 -130.42%
2016 -201.90 -28.02%
2015 -280.48 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber